Wayrilz (Rilzabrutinib) Dosage and Usage

Wayrilz (Rilzabrutinib) is a medicine indicated for the treatment of persistent or chronic immune thrombocytopenia (ITP) in adults who have had an inadequate response to prior therapy. Its use requires specific usage and dosage to ensure patient safety and therapeutic efficacy.

Before using Wayrilz, the pregnancy status of women of reproductive potential first needs to be verified to avoid potential effects of the drug on pregnancy. The recommended dose of Wayrilz is 400 mg taken by mouth twice daily. Patients can choose to take the drug at approximately the same time each day, with or without food. In patients with gastrointestinal symptoms, taking the drug with food can help improve the tolerability of the drug, thereby reducing the occurrence of adverse reactions.

If a patient misses a doseWayrilz should be taken on the same day as soon as possible, but at least 2 hours before the next regular dose. Additionally, when taking antacids or histamine H2 receptor antagonists, it is recommended to take Wayrilz at least 2 hours before taking these medications to avoid drug-drug interactions.

During treatment, monitoring of the patient's liver function is critical. Physicians should assess bilirubin and aminotransferase levels at baseline and monitor patients closely for clinical indications during treatment with Wayrilz. If patients develop abnormal liver function after treatment, liver function and related symptoms need to be monitored more frequently. If drug-induced liver injury (DILI) is suspected, Wayrilz should be discontinued immediately and once DILI is confirmed, use of the drug should be discontinued.

By following these usage and dosage guidelines, patients can use Wayrilz more safely while maximizing the drug's therapeutic effects. Patients should maintain good communication with their doctors during medication and report their physical conditions in a timely manner so that appropriate adjustments and management can be made. Overall, Wayrilz provides an important treatment option for ITP patients, but safe administration remains a top priority.

Reference materials:https://go.drugbank.com/drugs/DB17709